Top Stories
Top Stories
Health and Science

Drug deal to target cancer at genetic level: CEO

Great day for Foundation Medicine: CEO

Roche Holding has agreed to buy a majority stake in U.S.-based molecular and genomic analysis firm Foundation Medicine for up to $1.18 billion, in a move to bolster the Swiss drugmaker's personalized cancer treatments.

Dr. Michael J. Pellini, chief executive of Foundation, told CNBC on Monday the deal can accelerate a move into precision medicine for oncology.

"It's an important day for patients battling cancer," he said in a "Squawk Box " interview, noting that Foundation helps doctors understand cancer at its blueprint and then deploy targeted therapeutics.

Roche will pay $50 a share, or about $780 million, a premium of 109 percent to Foundation's closing price Friday. Roche will also invest $250 million in Foundation by acquiring newly issued shares.

As a result, Roche will own 52.4 percent to 56.3 percent of Foundation. The companies said the deal includes the potential for more than $150 million in additional funding by Roche.

—Reuters contributed to this report.

Sign Up for Our Newsletter Morning Squawk

CNBC's before the bell news roundup
Get this delivered to your inbox, and more info about about our products and services.
By signing up for newsletters, you are agreeing to our Terms of Use and Privacy Policy.